Safety and Feasibility of Kefir Administration in Critically Ill Adults

Overview

About this study

The purpose of this study is to evaluate the safety and feasibility of kefir administration in critically ill adults.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Critically ill adult (>18 years old) patients and expected to have >48-hour ICU stay.
  • Functional GI tract (able to tolerate oral diet or tube feeding).

Exclusion Criteria:

  • Premorbid known immunosuppression over 1 month duration (due to medications including chronic steroids, TNF-alpha inhibitors, monoclonal antibodies, immunosuppressive antimetabolites, etc.).
  • Compromised gut integrity (bowel resection, GI malignancy, GI bleed, inflammatory bowel disease, intestinal obstruction, intra-abdominal hypertension, intestinal ischemia/reperfusion injury or secondary ileus).
  • Dairy intolerance or milk allergy.
  • Extremely poor prognosis and not expected to survive the treatment period.
  • Goals of care change to comfort care.
  • Pregnant patients.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Lioudmila Karnatovskaia, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available
.
CLS-20536105

Mayo Clinic Footer